GRCE vs KMB · $35.0M cap vs P/E 19, rev $20.06B
Grace Therapeutics, Inc. (GRCE) versus Kimberly-Clark Corporation (KMB) — a side-by-side from cached financials, not a winner call.
Grace Therapeutics, Inc. (GRCE) is a biotechnology company listed on US.
Kimberly-Clark Corporation (KMB) is a household & personal products company listed on US.
GRCE does not have a complete income-statement cache yet.
Latest reported KMB revenue for 2024-12-31 was $20.06B. Net income was $2.58B. Revenue was down 1.8% from 2023-12-31 to 2024-12-31. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
GRCE currently screens at market cap $35.0M. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
Not investment advice. Open the GRCE and KMB stock pages for the full models.
Not investment advice.